Dilutionskoagulopathie

Zusammenfassung

Große Blutverluste werden akut, solange keine Frischplasmen zur Verfügung stehen, in erster Linie durch Kristalloide, Kolloide und Erythrozytenkonzentrate ersetzt, so dass eine Verdünnung aller plasmatischer Gerinnungsfaktoren resultiert. Eine blutungsbedingte Verlustkoagulopathie geht daher nahezu immer mit einer Verdünnungskoagulopathie einher. Formeln zur Berechnung kritischer Blutverluste sowie Standardgerinnungstests sind im Falle einer Massivtransfusion oft nicht hilfreich. Demgegenüber haben Pointof- care taugliche Systeme wie die Thrombelastographie, bedeutende Vorteile.

Im Rahmen der Verlust- und Dilutionskoagulopathie ist zunächst die plasmatische Gerinnung gestört, wobei Fibrinogen als erstes kritische Werte zu erreichen scheint. Dabei wird die Fibrinpolymerisation nicht nur durch den blutungsbedingten Fibrinogenverlust und Verdünnung beeinträchtigt, sondern auch durch die Interaktion mit künstlichen Kolloiden, insbesondere durch Hydroxyethylstärke-haltige Präparate.

Weder die Therapie mit Frischplasmen, noch die Behandlung mit Gerinnungsfaktorenkonzentraten wurde in ausreichendem Maße klinisch untersucht. Es werden weitere Studien notwendig sein um Richtlinien erarbeiten zu können, wie Gerinnungsmanagement im Rahmen großer Blutverluste zu erfolgen hat.

Summary

When no fresh frozen plasma is available, acute major blood loss is compensated above all with crystalloids, colloids and red blood cell concentrates, meaning that all plasma clotting factors are diluted. Consumption coagulopathy is almost always accompanied by dilutional coagulopathy. Formulas for calculating critical blood loss and standard coagulation tests are often not helpful in the case of massive transfusion. On the other hand, systems suitable for point of care, such as thrombelastography, have important advantages. In the case of consumption and dilutional coagulopathy plasma coagulation is disturbed and critical values are first seen for fibrinogen. Not only is fibrin polymerization impaired by the bleeding-induced loss and dilution of fibrinogen, but also by interaction with artificial colloids, particularly hydroxyethyl starch preparations. Therapy of consumption and dilutional coagulopathy calls for fresh frozen plasma. If this is not available in sufficient quantity or within a reasonable time, coagulation factor concentrates must be used. Neither fresh frozen plasma therapy nor treatment with coagulation factor concentrates has been the subject of detailed clinical study. Further studies are needed to work out guidelines for coagulation management in the case of massive blood loss.

Schlüsselwörter

Blutverlust - Dilutionskoagulopathie - Thrombelastographie - Gerinnungsmanagement

Keywords

Blood loss - dilutional coagulopathy - thrombelastography - coagulation management

• Literatur

• 1 Calatzis AN, Kling M, Calatzis AL. et al. Fast and specific coagulation monitoring through modified thrombelastography. Ann Hematol 1996; 72 Suppl I P92.
• 2 Choi P, Yip G, Quinonez LG. et al. Crystalloids vs. colloids in fluid resuscitation. A systemic review. Crit Care Med 1999; 27: 200-21.
• 3 Ciaverella D, Reed RL, Counts RB. et al. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br J Haematol 1987; 67: 365-8.
• 4 Escolar G, Garrido M, Mazzara R. et al. Experimental basis for the use of red cell transfusion in the management of anaemic-thrombocytopenic patients. Transfusion 1988; 28: 406-11.
• 5 Fries D, Innerhofer P, Klingler A. et al. The effect of the combined administration of colloids and lactated Ringer’s solution on the coagulation system: an in vitro study using thrombelastograph coagulation analysis. Anesth Analg 2002; 94: 1280-7.
• 6 Fries D, Krismer A, Klingler A. et al. The effect of fibrinogen on reversal of dilutional coagulopathy: a porcine model. Br J Anaesth 2005; 95: 172-7.
• 7 Fries D, Streif W, Klingler A. et al. The effect of fibrinogen substitution on reversal of dilutional coagulopathy: a case report serial and an in-vitro model. Anesth Analg 2006; 102: 347-51.
• 8 Gentillelo LM, Pierson DJ. Trauma critical care. Am J Respir Crit Care Med 2001; 163: 604-7.
• 9 Hiippala ST, Myllylä GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma poor red cell concentrates. Anesth Analg 1995; 81: 360-5.
• 10 Hiippala ST. Dextran and hydroxyethylstarch interfere with fibrinogen assays. Blood Coagul Fibrinolysis 1995; 6: 743-746.
• 11 Innerhofer P, Fries D, Klingler A, Streif W. In vivo effects of haemodilution with saline on coagulation. Br J Anaesth 2002; 89: 934-9.
• 12 Innerhofer P, Fries D, Margreiter J. et al. The effect of perioperatively administered colloids and crystalloids on primary hemostasis and clot formation. Anesth Analg 2002; 95: 858-65.
• 13 Leslie SD, Toy PTCY. Laboratory hemostatic abnormalities in massively transfused patients given red blood cells and crystalloids. Am J Clin Pathol 1991; 96: 224-32.
• 14 Mardel SN, Saunders FM, Allen H. et al. Reduced clot quality of clot formation with gelatin based plasma substitutes. Br JAnaesth 1998; 80: 204-7.
• 15 McLoughlin TM, Fontana JL, Alving B. et al. Profound normovolemic hemodilution: hemostatic effects in patients and in a porcine model. Anesth Analg 1996; 83: 459-65.
• 16 Murray DJ, Olson J, Strauss R. et al. Coagulation changes during packed red cell replacement of major blood loss. Anesthesiology 1988; 69: 839-45.
• 17 Murray DJ, Pennell BJ, Weinstein SL. et al. Packed red cells in acute blood loss: dilutional coagulopathy as a cause of surgical bleeding. Anesth Analg 1995; 80: 336-42.
• 18 Ng KFJ, Lam CCK, Chan LC. In vivo effects of haemodilution with saline on coagulation: a randomized controlled trial. Br J Anaesth 2002; 88: 475-80.
• 19 Petroianu GA, Maleck WH, Koettner KP. et al. Effect of in vitro hemodilution with hydroxyethylstarch and dextrans on the activity of plasma clotting factors. Crit Care Med 2003; 31: 250-4.
• 20 Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solution in critically il patients: a systemic review of randomized trials. Br Med J 1998; 316: 961-4.
• 21 Singbartl K, Innerhofer P, Radvan J. et al. Hemostasis and hemodilution–a quantitative-mathematical guide for clinical practice. Anesth Analg 2003; 96: 929-35.
• 22 Spiess BD, Gillies BS, Chandler W. et al. Changes in transfused therapy and reexploration rate after institution of a blood management programm in cardiac surgical patients. J Cardiothorac Vasc Anesth 1995; 9: 168-73.
• 23 Treib J, Baron JF, Grauer MT. et al. An international view of hydroxyethyl starches. Int Care Med 1999; 25: 258-68.
• 24 Valeri CR, Cassidy G, Pivacek LE. et al. Anemia induced increase in bleeding time: the implication for treatment of nonsurgical blood loss. Transfusion 2001; 41: 977-83.
• 15 Vorstand und wissenschaftlicher Beirat der Bundesärztekammer. Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. Deutscher Ärzteverlag Köln. 2001